Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Croi 2014 Location"

09:32 EDT 31st July 2014 | BioPortfolio

Original Source: 20th Conference on Retroviruses and Opportunistic Infections (CROI)

Read clinically focused news coverage of key developments from CROI 2013. Medscape HIV/AIDS

Matching Channels

Serine Threonine protein kinase C PKC

The serine/threonine protein kinase C (PKC) family consists of at least 11 mammalian isozymes belonging to a larger subclass of protein kinases termed the adenine-guanine-cytosine (AGC) kinases. PK...

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

Tinnitus

Tinnitus causes people to hear constant sounds in one ear, both ears or in their head. Tinnitus is the medical name for the perception of noise in one ear, both ears or in the head. The noise comes...

Matching News

2014 Conference on Retroviruses and Opportunistic Infections (CROI)

Read clinically focused news coverage of key developments from CROI 2014. Medscape HIV/AIDS

Coming This Week: Reports From AAAAI and CROI, Pot and RA

(MedPage Today) -- March is roaring in like a lion with research news from two major medical meetings: the American Academy of Allergy, Asthma and Immunology (AAAAI) and the Conference on Retroviruses...

Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, recently announced that new in vitro...

AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C

BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and...

Selecting an Initial ART Regimen: Lessons From ACTG 5257

Drs. Paul Sax and Raphael Landovitz discuss the results from ACTG 5257 presented at CROI 2014 and the broader issues related to selecting an initial ART regimen for HIV infection. Medscape HIV/AIDS

CROI: TB, HCV in Spotlight Along With HIV

BOSTON (MedPage Today) -- The central focus of the annual Conference on Retroviruses and Opportunistic Infections is always HIV itself, but tuberculosis and hepatitis C will share the stage next week.

Dr. Schultz Relocates Superior Health from Waukegan to Gurnee

Sometimes to server more people, better service, we have to just up and move our business. That is what Superior Health decided to did. Gurnee, IL (PRWEB) April 02, 2014 Dr. Schultz at Superior Healt...

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

USA pharma giant Merck & Co subsidiary MSD says that in a 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-naive...

Matching PubMed Articles

CROI 2014: neurologic complications of HIV infection.

A shift in focus in the field of neuroHIV was clearly manifest at the 2014 Conference on Retroviruses and Opportunistic Infections (CROI), where a major emphasis was on the milder forms of neurologic...

CROI 2014: viral hepatitis and complications of HIV disease and antiretroviral therapy.

The remarkable advances in interferon-sparing, all-oral hepatitis C virus (HCV) treatment were a highlight of the 2014 Conference on Retroviruses and Opportunistic Infections (CROI). The backbone of t...

CROI 2014: advances in antiretroviral therapy.

The 2014 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted important advances in antiretroviral therapy, with an emphasis on HIV eradication strategies. Follow-up information...

Highlights from the 21st CROI.

CROI 2014: basic science review.

In the HIV basic science categories of the 2014 Conference on Retroviruses and Opportunistic Infections, research examining obstacles to viral eradication continued to be a major component. This resea...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement